Greenfield Savings Bank decreased its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 3.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,299 shares of the medical research company’s stock after selling 112 shares during the quarter. Greenfield Savings Bank’s holdings in Amgen were worth $860,000 at the end of the most recent quarter.
Several other large investors have also modified their holdings of AMGN. Leibman Financial Services Inc. raised its stake in shares of Amgen by 6.8% in the 4th quarter. Leibman Financial Services Inc. now owns 12,800 shares of the medical research company’s stock valued at $3,336,000 after acquiring an additional 818 shares during the period. Exeter Financial LLC raised its holdings in shares of Amgen by 2.8% in the 4th quarter. Exeter Financial LLC now owns 11,424 shares of the medical research company’s stock valued at $2,978,000 after buying an additional 313 shares during the period. PSI Advisors LLC lifted its stake in Amgen by 25.1% during the 4th quarter. PSI Advisors LLC now owns 503 shares of the medical research company’s stock worth $131,000 after acquiring an additional 101 shares in the last quarter. Granite Bay Wealth Management LLC grew its position in Amgen by 6.7% in the 4th quarter. Granite Bay Wealth Management LLC now owns 16,069 shares of the medical research company’s stock valued at $4,188,000 after acquiring an additional 1,005 shares in the last quarter. Finally, First Financial Corp IN increased its stake in Amgen by 65.8% during the fourth quarter. First Financial Corp IN now owns 539 shares of the medical research company’s stock worth $140,000 after purchasing an additional 214 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.
Amgen Stock Up 3.0 %
Shares of AMGN stock opened at $270.19 on Tuesday. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The stock has a 50 day moving average of $278.16 and a 200-day moving average of $308.35. The firm has a market cap of $145.24 billion, a PE ratio of 34.60, a price-to-earnings-growth ratio of 2.91 and a beta of 0.56.
Amgen Increases Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be paid a $2.38 dividend. The ex-dividend date is Friday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 dividend on an annualized basis and a yield of 3.52%. Amgen’s dividend payout ratio (DPR) is presently 121.90%.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on AMGN. Cantor Fitzgerald reiterated an “overweight” rating and issued a $405.00 price objective on shares of Amgen in a research note on Tuesday, October 22nd. UBS Group dropped their price target on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a research note on Thursday, October 31st. Jefferies Financial Group restated a “buy” rating and issued a $380.00 price objective on shares of Amgen in a research note on Tuesday, November 12th. TD Cowen boosted their price objective on Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Finally, William Blair reaffirmed an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $314.91.
Get Our Latest Analysis on AMGN
About Amgen
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
See Also
- Five stocks we like better than Amgen
- Top Biotech Stocks: Exploring Innovation Opportunities
- Analyst Upgrade Shows Over Double Bagger Potential for BigBear.ai
- How to Invest in Blue Chip Stocks
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- Why Invest in 5G? How to Invest in 5G Stocks
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.